A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona mutacja genu EGFR w guzie
- •Zaawansowany rak płuca, który rozprzestrzenia się lub powraca
- •Zdolność przełykania kapsułek
- •Dobry ogólny stan zdrowia
- •Możliwość podpisania zgody na udział w badaniu
- •Brak lepszych dostępnych opcji leczenia lub leczenie standardowe nie jest możliwe
- •Kobiety w wieku rozrodczym muszą stosować antykoncepcję przez 7 miesięcy po badaniu, mężczyźni przez 6 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
Southern Oncology Clinical Research Unit
Bedford Park, Australia
Monash Medical Centre Clayton
Clayton, Australia
Princess Margaret Cancer Centre
Toronto, Canada
AP-HM Hôpital Nord
Marseille, France
Centre Georges François Leclerc
Dijon, France
Prince of Wales Hospital
Hong Kong, Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
Hospital Umum Sarawak
Kuching, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Institut Kanser Negara
Putrajaya, Malaysia
National Cancer Centre Singapore
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Seoul National University Bundang Hospital
Seongnam-si, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, South Korea
Chungbuk National University Hospital
Cheongju-si, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Badalona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Regional Universitario de Málaga - Hospital Civil
Málaga, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Phramongkutklao Hospital
Thung Phaya Thai, Thailand
Songklanagarind Hospital Prince of Songkla University
Hat Yai, Thailand
Trial contact
Somi Lee
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.